Boards
News
Market Data
Markets
Discover
Discover
AI Subscribe Login/Register account icon
S&P 500
6,816.89
(
-0.11%
)
US TECH 100
24,442.80
(
0.00%
)
Dow Jones
47,916.57
(
-0.56%
)
Brent Oil
98.72
(
-1.14%
)
Bitcoin
70,846.01
(
0.10%
)
News Focus
News Focus
Post# of 9090
Next 10
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 843
Posts 122862
Boards Moderated 9
Alias Born 09/05/2002

DewDiligence

Member Level

Re: mouton29 post# 2819

Tuesday, 10/11/2022 5:22:05 PM

Tuesday, October 11, 2022 5:22:05 PM

Post# of 9090
It’s preposterous for Morgan Stanley to model zero loss of market share by Botox out to 2030. Moreover, the excerpt you posted makes no mention of Daxxify’s sales in therapeutic indications, which will surely be contributing well before 2030.

Daxxify’s fewer visits issue is a red herring, IMO. Injectors are seeking more profit per patient visit, not more visits per se.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Detailed Quote